Here is the design of a clinical trial:

Official Title: The Effect of Weekly Injection of Teriparatide on the Healing of Distal Radius Fracture in a Double-blind, Randomized Controlled Clinical Trial

Included conditions:
- Colles' Fracture

Study Armgroups:
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Injection product without active teriparatide', 'interventionNames': ['Drug: Placebo']}
- {'label': 'PTH 40ug/w', 'type': 'EXPERIMENTAL', 'description': 'Injection product with active teriparatide', 'interventionNames': ['Drug: recombinant teriparatide for injection']}

Interventions:
- {'type': 'DRUG', 'name': 'recombinant teriparatide for injection', 'description': 'weekly subcutaneous administration of 40 ug', 'armGroupLabels': ['PTH 40ug/w'], 'otherNames': ['Xinfutai']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'weekly subcutaneous administration of 40 ug', 'armGroupLabels': ['Placebo'], 'otherNames': ['Xinfutai placebo']}

Primary Outcomes:
- {'measure': 'The median time of radiographic healing', 'description': 'A score of 13 by Modified Radiographic Union Scale for Tibia fractures (mRUST) scoring system would provide a confident assessment of union', 'timeFrame': '0-14 weeks'}

Please estimate the sample size based on the assumption: 
Loss to follow-up rate of 20%, power of 80%, significance level (Î±) of 5%, and standard deviation (SD) of 2.2.
Sample size
        Based on the results of a similar clinical study,18 we predicted a difference in fracture healing time between groups of approximately 1.5 weeks. Assuming a loss to follow-up rate of 20%, each group will need to contain 40 patients to achieve a power of 80%, with an Î± value of 5% and SD of 2.2.